Reducing the Harm Caused by Smoking
HQ: Williamsville, NY
Facility: N Carolina
Symbol/Exchanges: XXII (NYSE)
CEO: Henry Sicignano
22nd Century is a plant biotech company focused on developing technology to control the amount of nicotine in tobacco (primarily lower it to reduce harm)—and the level of cannabinoids in cannabis, through plant breeding and genetics. Both of these are potentially “hot” future commercial areas.
Market Cap: US$ 336 mil
Enterprise Value: $279 mil
Primary: US, France, Europe
Vertically integrated: No
Horizontally diversified: Yes, it has interests in both tobacco and cannabis, for example.
Current share price: $2.71
Price to Sales: 14.3 (Tobacco industry = 5) (Pharmaceutical industry=7)
EV / revenue: 11.9
EV / revenue rank in industry: NA
Their SPECTRUM line features 24 styles, in regular and menthol versions, with a fixed level of tar but 8 different levels of nicotine. These vary from Very Low Nicotine (VLN) cigarettes (97% less than normal) to relatively high nicotine yields.